Recombinant human interferon α2b(Beijing Yuance)

重组人干扰素α2b（北京远策）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interferon α2b(Beijing Yuance)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsUrinary Bladder NeoplasmsOvarian NeoplasmsMultiple Myeloma +[13] 
Global Approved IndicationsUrinary Bladder NeoplasmsOvarian NeoplasmsMultiple Myeloma +[13] 
Approved Indications in ChinaUrinary Bladder NeoplasmsOvarian NeoplasmsMultiple Myeloma +[13] 
Original Approved Country/TerritoryMainland China
Original Approved Date1999/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Yuance Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Yuance Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsOvarian NeoplasmsMultiple Myeloma +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A